For the last five years, the quarterly Scandinavian Life Science Journal has covered the biotech, pharma and medical technology markets in Scandinavia. The journal has followed the trends and market tendencies and developed with them. Given the boundless nature of research our clients can be found in almost all parts of the world. Since the start in 2003, we have established constructive collaborations regarding distribution and editorial content with leading European life science clusters and organisations.

As a region, Scandinavia has performed very well within the life sciences. And for the last five years, Scandinavian Life Science Journal has presented clusters, companies, organisations, universities, research groups and individual scientists to a broad readership.
However, we now feel that it’s time to broaden our horizon geographically, to cover more of the interesting science, business and cross-border collaborations taking place all over Europe. Hence, this is the very last issue of the Scandinavian Life Science Journal. The journal changes name to European Life Science Journal (ELSJ) with issue #1/2008.

Over the years, the distribution of the Scandinavian Life Science Journal (including the on-line version) has expanded well beyond Scandinavia, and has been appreciated in North America, Asia and the Middle East. With the European Life Science Journal we are confident that we will reach an even greater audience and stir interest in more areas of Europe and the world.

Scandinavian Life Science Journal started the same year as SwedenBIO was established. And in this issue you get some glimpses from the leading Swedish biotech business organisation’s latest annual CEO summit, where the issue of M&As dominated the agenda and a member survey was presented.

Also, the Finnish life science sector see a period of consolidation as the Scandinavian biotech markets mature and catch up with their European counterparts. However, the US is of course still the big goal for any life science enterprise. But there are alternatives. Canada, the Middle East and Asia are all competing to attract the best talents and most promising businesses from Europe, boasting with generous tax incentives, closeness to big markets and easy access to skilled labour.

And in Europe the reverse is true. We want the most talented, skilled and commercially driven people to settle here. We live in a very exciting time, where we witness an extraordinary brain circulation around the world. And maybe, just maybe, you’ll find your next partnering organisation between these covers or in the future issues of the European Life Science Journal.
 
 
Anders Lindgren
Editor-in-Chief